Table 3. Sensitivity, specificity and r2 of the included studies.
| AUTHOR, YEAR | SENSITIVITY | SPECIFICITY | CORRELATION (R2) OF ANTIBODY LEVELS IN DBS AND SERUM/PLASMA |
|---|---|---|---|
| GIL A, 1997 [14] | 91.30% | 99.30% | Nr |
| MELGACO J, 2011 [15] | 100% | 100% | 0.6262 |
| FLORES L, 2018 [16] | Anti-HBs in HIV- individuals: 79.8% Anti-HBs in HIV+ individuals: 76.8% |
Nr | Nr |
| VILLAR M, 2011 [17] | HBsAg: 95.45%; Anti-HBc: 89.19%; Anti-HBs: 83.05% |
HBsAg: 70.79%; Anti-HBc: 97.53%; Anti-HBs: 81.33% | 0.832 |
| MOHAMED S, 2013 [18] | 98% | 100% | 0.98 |
| DOKUBO K, 2014 [19] | Anti-HCV: 70% | Anti-HCV: 100% | 0.69 |
| TEJADA-STROP A, 2015 [20] | CIA- 100%; ELISA- 97% | CIA- 100%; ELISA- 100% | Nr |
| TUAILLON E, 2010 [21] | 99% | 98% | Nr |
| BRANDAO C, 2013 [22] | 95.00% | 100% | 0.971 |
| SARGE-NIJE R, 2006 [23] | Ranged from 95% to 100% [depending on which assay was used] | Ranged from 97.5% to 100% [depending on which assay was used] | Nr |
| CASTRO A, 2008 [24] | 100% | 99.60% | Nr |
| BOILLOT F, 1997 [25] | 87.50% | 100% | Nr |
| KANIA D, 2013 [26] | HBsAg: 96%; Anti-HBc: 99.3%; HIV: 100%; HCV: 100% |
HBsAg: 100%; Anti-HBc: 98.7%; HIV: 100%; HCV: 100% |
HBsAg: 0.98; Anti-HBc: 0.98; HIV: 1.00; HCV: 1.00 |
| ROSS S, 2013 [27] | HBsAg: 98.6%; Anti-HBc: 97.1%; Anti-HBs: 97.5%; Anti-HCV: 97.8%; Anti-HIV ½: 100% |
HBsAg: 100%; Anti-HBc: 100%; Anti-HBs: 100%; Anti-HCV: 100%; Anti-HIV ½: 100% |
Nr |
| LEE C, 2011 [28] | HIV: 100%; HBsAg: 96.5%; Anti-HBs: 74.2%; Anti-HCV: 100% |
HIV: 100%; HBsAg: 97.8%; Anti-HBs: 86.9%; Anti-HCV: 100% |
HIV Ag/Ab: 0.824; HBsAg: 0.432; Anti-HBs: 0.721; Anti-HCV: 0.631 |
| BHATIA R, 2019 [29] | Nr | Nr | Nr |
| LOUIE K, 2018 [30] | 94% | 98% | 0.961 |
| UZICANIN A, 2011 [31] | Measles (week 1 after rash): 98.7% Non-measles: 50% |
Measles (week 1 after rash): 88.9% Non-measles: 100% |
Measles (week 1 after rash): 0.71 Non-measles: 0.33 |
| COLSON K, 2015 [32] | 100% | 96.8% | 0.92 |
| PUNNARUGSA V, 1991 [33] | 99.40% | 100% | Nr |
| HELFAND F, 2007 [34] | IgM: 82% IgG: 89% |
Nr | IgM: 0.91 IgG: 0.94 |
| HOLGUIN A, 2013 [35] | 98.80% | 71.60% | 0.803 |
| EICK G, 2017 [36] | Nr | Nr | 0.93 |
| WATERBOER T, 2012 [37] | HPV: 94.5%; H. pylori: 96.6%; HCV: 98%; Polyomavirus: 98% |
Nr |
H. pylori, HCV, JCV: 0.88; HPV: 0.79 |
| DUARTE E, 2002 [38] | Nr | Nr | 0.95 |
| FORMENTI F, 2016 [39] | Nr | Nr | 0.921 |
| SMIT P, 2013 [40] | TPPA: 85.4% TPHA: 50.5% ELISA: 94.6% |
TPPA: 98.9% TPHA: 99.7% ELISA: 50.4% |
Nr |
| VAN OMMEN C, 2012 [41] | Nr | Nr | 0.91 |
| CONDORELLI F, 1994 [42] | Measles: 98.6%; Mumps: 96%; Rubella: 99.1% |
Nr | Nr |
| AABYE M, 2012 [43] | Nr | Nr | Nr |
| HEGAZY M, 2020 [44] | 100% | 100% | Nr |
| GEERTS M, 2020 [45] | 92.6% | 100% | Nr |
| MA J, 2020 [46] | Anti-HCV: 98.32% Anti-HIV: 88.46% Anti-TP: 92.19% |
Anti-HCV: 100% Anti-HIV: 100% Anti-TP: 100% |
Anti-HCV: 0.99 Anti-HIV: 0.96 Anti-TP: 0.95 |
| KUMAR A, [47] | Anti-H. pylori: 87.5% | Anti-H. pylori: 95% | Nr |
| VILLAR L, 2020 [48] | HBsAg: 100%; Anti-HBc: 66.6%; Anti-HCV: 75% |
HBsAg: 98.9%; Anti-HBc: 99.8%; Anti-HCV: 99.8% |
Nr |
| ROSAS-AGUIRRE A, 2020 [49] | 35.2% | 83.5% | Nr |
| STEFIC K, 2019 [50] | 98.9% | Nr | Nr |
| CRUZ H, 2020 [51] | HBsAg: 81.2% Anti-HBc: 66.5% Anti-HBs: 60% |
HBsAg: 93.5% Anti-HBc: 99.3% Anti-HBs: 75.1% |
Nr |
| MORLEY G, 2020 [52] | 98.11% | 100% | 0.975 |
Abbreviations: a anti-HBc: Hepatitis B core antibody; b anti-HBs: Hepatitis B surface antibody; c CIA: Chemiluminescence immunoassay; d ELISA: Enzyme-linked immunosorbent assay; e HAV: Hepatitis A virus; f HCV: Hepatitis C virus; g HIV: Human Immunodeficiency virus; h HPV: Human papillomavirus; i HBsAg: Hepatitis B surface antigen j Nr: Not reported; k TPPA: Treponema pallidum particle agglutination assay; l TPHA: Treponema pallidum hemagglutination assay.